Multifocal HD-tDCS and Motor Function
Launched by UNIVERSITY OF MICHIGAN · Aug 16, 2024
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how a technique called High-density transcranial direct current stimulation (HD-tDCS) can help improve hand movement and coordination. The study aims to learn more about how the brain controls movement and whether a personalized approach to brain stimulation can enhance these effects even further. Participants will be assigned to receive either a standard treatment or a customized version of the HD-tDCS to see which one works better for improving hand function.
To be eligible for this study, participants should be healthy, right-handed individuals aged between 18 and 45, and they must be able to understand English and provide written consent. Certain conditions, like being left-handed, having a neurological disorder, or being pregnant, may disqualify someone from participating. If you join the study, you will undergo brain stimulation sessions and may experience improvements in your dexterous hand movements. This research could provide valuable insights into how brain stimulation can enhance motor function for various applications in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants should be in good health with normal or corrected-to-normal visual acuity
- • Right handed
- • No history of neurological disorder
- • English speaker
- • Able to provide written consent prior to admission
- Exclusion Criteria:
- • Left-handed
- • Participants are pregnant, suspect pregnancy or are attempting to become pregnant
- • Have a pacemaker, intracardiac lines or any other medically implanted device or medicine pump
- • Have cochlear hearing implants
- • Taking drugs known to influence neural receptors that facilitate neuroplasticity (see protocol)
- • Have non removable body piercings or have foreign objects in body
- • Have metal anywhere in the head that could increase risk of serious injury (not including braces, dental fillings, etc.) (see protocol)
- • Have a personal or family history of seizure/epilepsy
- • Taking prescription drugs that lower the threshold for seizures
- • Recent history of excessive alcohol consumption
- • History of alcohol addiction/dependence
- • Recent history of recreational drug use
- • History of drug addiction/dependence
- • Recent history of recreational drug use
- • History of drug addiction/dependence
- • Diagnosed with a stroke, brain hemorrhage, brain tumor, encephalitis.
- • Diagnosed with multiple sclerosis
- • Diagnosed with Parkinson's disease or Alzheimer's disease
- • Diagnosed with depression in the past 6 months
- • Diagnosed with attention deficit disorder, schizophrenia, manic depressive (bipolar) disorder
- • Diagnosed with normal pressure hydrocephalus or increased intra-cranial pressure
- • Diabetes requiring insulin treatment
- • Any serious heart disorder or liver disease
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Michael Vesia, PhD
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported